Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Dr. David Eric CohenIndependent Director | -6,06k | 123,09k | Automatic Disposition | 20,21 - 21,38 | 17,61k | -25,59% |
| 2026-06-01 | Dr. Jeegar PatelChief Scientific Officer | -13,51k | 255,38k | Derivative Exercise and Sale | 3,84 - 22,74 | 5,97k | - |
| 2026-06-01 | Dr. Jeegar PatelChief Scientific Officer | -3,18k | 72,20k | Automatic Disposition | 22,74 | 5,97k | -34,73% |
| 2026-06-01 | Mr. Luis C. PenaFounder, President, CEO & Director | -16,79k | 381,74k | Automatic Disposition | 22,74 | 496,14k | -3,27% |
| 2026-05-28 | Mr. Gregory S. MossChief Business & Legal Officer, Corporate Secretary and CCO | -14,22k | 300,39k | Derivative Exercise and Sale | 1,71 - 22,83 | 8,17k | - |
| 2026-05-28 | Mr. Kyle CarverCFO | -15,00k | 297,75k | Derivative Exercise and Sale | 2,99 - 22,84 | 4,87k | - |
| 2026-05-28 | Mr. Kyle CarverCFO | -3,18k | 72,52k | Automatic Disposition | 22,84 | 4,87k | -39,49% |
| 2025-12-19 | Dr. Robert L. HopfnerIndependent Director | 1.000,00 | 17,35k | Kauf | 17,35 | 4,03k | 33,05% |
| 2025-12-09 | Dr. Jeegar PatelChief Scientific Officer | -7,51k | 134,03k | Sale to Issuer | 17,84 | 9,14k | -45,11% |
| 2025-12-09 | Mr. Luis C. PenaFounder, President, CEO & Director | -28,14k | 501,98k | Sale to Issuer | 17,84 | 512,93k | -5,20% |
| 2025-12-09 | Mr. Gregory S. MossChief Business & Legal Officer, Corporate Secretary and CCO | -13,62k | 243,05k | Sale to Issuer | 17,84 | 8,17k | -62,52% |
| 2025-12-09 | Mr. Kyle CarverCFO | -13,29k | 237,09k | Sale to Issuer | 17,84 | 8,04k | -62,30% |
| 2025-12-09 | Ms. Janice DrewChief of Development Operations | -5,07k | 90,52k | Sale to Issuer | 17,84 | 40,75k | -11,07% |
| 2025-12-09 | Dr. Eugene Andrew BauerCo-Founder, Chief Medical Officer & Director | -1,48k | 26,37k | Sale to Issuer | 17,84 | 262,05k | -0,56% |
| 2025-11-07 | RA Capital Management, L.P.Unternehmen | 2,21M | 0,00 | Derivative Exercise and Retained Stock | - | 3,46M | 176,70% |
| 2025-11-07 | RA Capital Management, L.P.Unternehmen | 1,25M | 20,00M | Kauf | 16,00 | 3,46M | 56,59% |
| 2025-11-07 | Eqt Fund Management S.à R.L.Unternehmen | 3,37M | 0,00 | Derivative Exercise and Retained Stock | - | 4,93M | 215,50% |
| 2025-11-07 | Eqt Fund Management S.à R.L.Unternehmen | 1,56M | 25,00M | Kauf | 16,00 | 4,93M | 46,40% |
| 2025-11-07 | Mr. Luis C. PenaFounder, President, CEO & Director | 24,23k | 0,00 | Derivative Exercise and Retained Stock | - | 493,82k | 5,16% |
| 2025-11-07 | Dr. Jeegar PatelChief Scientific Officer | 3,18k | 0,00 | Derivative Exercise and Retained Stock | - | 3,18k | - |
| 2025-11-07 | Mr. Gregory S. MossChief Business & Legal Officer, Corporate Secretary and CCO | 3,18k | 0,00 | Derivative Exercise and Retained Stock | - | 3,18k | - |
| 2025-11-07 | Dr. Robert L. HopfnerIndependent Director | 3,03k | 0,00 | Derivative Exercise and Retained Stock | - | 3,03k | - |
| 2025-11-07 | Pivotal BioVenture Partners LLCUnternehmen | 1,93M | 0,00 | Derivative Exercise and Retained Stock | - | 1,93M | - |
| 2025-11-07 | NFLS Delta III LimitedUnternehmen | 1,44M | 0,00 | Derivative Exercise and Retained Stock | - | 1,44M | - |
| 2025-11-07 | Ms. Janice DrewChief of Development Operations | 1,59k | 0,00 | Derivative Exercise and Retained Stock | - | 36,81k | 4,51% |
| 2025-11-07 | Dr. David Eric CohenIndependent Director | 6,06k | 0,00 | Derivative Exercise and Retained Stock | - | 23,67k | 34,39% |
| 2025-11-07 | Mr. Kyle CarverCFO | 3,18k | 0,00 | Derivative Exercise and Retained Stock | - | 3,18k | - |
| 2025-11-07 | Dr. Eugene Andrew BauerCo-Founder, Chief Medical Officer & Director | 25,81k | 0,00 | Derivative Exercise and Retained Stock | - | 260,61k | 10,99% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
